Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -59.58 Billion KRW | 69.36% |
| 2022 | -194.5 Billion KRW | -44.4% |
| 2021 | -134.69 Billion KRW | -330.73% |
| 2020 | -31.27 Billion KRW | 21.73% |
| 2019 | -39.95 Billion KRW | -974.24% |
| 2018 | -3.71 Billion KRW | -670.79% |
| 2017 | 651.61 Million KRW | -99.76% |
| 2016 | 265.98 Billion KRW | 1167.85% |
| 2015 | 20.97 Billion KRW | 76.96% |
| 2014 | 11.85 Billion KRW | 82.82% |
| 2013 | 6.48 Billion KRW | -61.6% |
| 2012 | 16.88 Billion KRW | -38.14% |
| 2011 | 27.29 Billion KRW | 46.87% |
| 2010 | 18.58 Billion KRW | -43.41% |
| 2009 | 32.84 Billion KRW | 81.09% |
| 2008 | 18.13 Billion KRW | -19.83% |
| 2007 | 22.62 Billion KRW | -2.13% |
| 2006 | 23.11 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -9.63 Billion KRW | -57.39% |
| 2024 Q1 | -6.12 Billion KRW | 44.74% |
| 2024 Q3 | -15.96 Billion KRW | -65.68% |
| 2023 Q3 | -25.55 Billion KRW | -142.51% |
| 2023 Q2 | -10.53 Billion KRW | 52.97% |
| 2023 Q1 | -22.4 Billion KRW | 73.49% |
| 2023 Q4 | -11.07 Billion KRW | 56.65% |
| 2023 FY | -59.58 Billion KRW | 69.36% |
| 2022 FY | -194.5 Billion KRW | -44.4% |
| 2022 Q1 | -128.33 Billion KRW | -155.54% |
| 2022 Q2 | 42.29 Billion KRW | 132.96% |
| 2022 Q3 | -23.94 Billion KRW | -156.62% |
| 2022 Q4 | -84.51 Billion KRW | -252.89% |
| 2021 Q3 | -6.36 Billion KRW | -646.95% |
| 2021 Q4 | -50.22 Billion KRW | -688.48% |
| 2021 Q1 | -13.44 Billion KRW | -8.35% |
| 2021 Q2 | -852.74 Million KRW | 93.66% |
| 2021 FY | -134.69 Billion KRW | -330.73% |
| 2020 Q4 | -12.4 Billion KRW | -137.03% |
| 2020 FY | -31.27 Billion KRW | 21.73% |
| 2020 Q1 | -2.57 Billion KRW | 92.8% |
| 2020 Q2 | 1.03 Billion KRW | 140.11% |
| 2020 Q3 | -5.23 Billion KRW | -607.33% |
| 2019 Q3 | 4.96 Billion KRW | 241.78% |
| 2019 FY | -39.95 Billion KRW | -974.24% |
| 2019 Q2 | 1.45 Billion KRW | -78.74% |
| 2019 Q4 | -35.71 Billion KRW | -819.01% |
| 2019 Q1 | 6.83 Billion KRW | 283.8% |
| 2018 Q3 | 438.11 Million KRW | 160.04% |
| 2018 Q1 | 292.22 Million KRW | -47.61% |
| 2018 FY | -3.71 Billion KRW | -670.79% |
| 2018 Q4 | -3.71 Billion KRW | -949.08% |
| 2018 Q2 | -729.75 Million KRW | -349.73% |
| 2017 Q3 | 519.35 Million KRW | 168.7% |
| 2017 Q2 | -756.02 Million KRW | -328.72% |
| 2017 Q1 | 330.54 Million KRW | 114.43% |
| 2017 FY | 651.61 Million KRW | -99.76% |
| 2017 Q4 | 557.73 Million KRW | 7.39% |
| 2016 Q4 | -2.29 Billion KRW | -100.9% |
| 2016 FY | 265.98 Billion KRW | 1167.85% |
| 2016 Q3 | 254.32 Billion KRW | 3460.75% |
| 2016 Q2 | 7.14 Billion KRW | 4.84% |
| 2016 Q1 | 6.81 Billion KRW | 191.75% |
| 2015 FY | 20.97 Billion KRW | 76.96% |
| 2015 Q1 | 8.95 Billion KRW | 396.55% |
| 2015 Q2 | 4.47 Billion KRW | -50.0% |
| 2015 Q3 | 5.15 Billion KRW | 15.12% |
| 2015 Q4 | 2.33 Billion KRW | -54.7% |
| 2014 Q4 | 1.8 Billion KRW | -57.91% |
| 2014 Q3 | 4.28 Billion KRW | 78.44% |
| 2014 Q2 | 2.4 Billion KRW | -28.61% |
| 2014 Q1 | 3.36 Billion KRW | -28.25% |
| 2014 FY | 11.85 Billion KRW | 82.82% |
| 2013 FY | 6.48 Billion KRW | -61.6% |
| 2013 Q4 | 4.68 Billion KRW | -45.6% |
| 2013 Q1 | 5.49 Billion KRW | -32.65% |
| 2013 Q3 | 8.61 Billion KRW | 171.2% |
| 2013 Q2 | -12.1 Billion KRW | -320.36% |
| 2012 FY | 16.88 Billion KRW | -38.14% |
| 2012 Q4 | 8.15 Billion KRW | 116.8% |
| 2012 Q3 | 3.76 Billion KRW | -41.35% |
| 2012 Q2 | 6.41 Billion KRW | 33419.8% |
| 2012 Q1 | 19.13 Million KRW | 0.0% |
| 2011 FY | 27.29 Billion KRW | 46.87% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 2.56 Billion KRW | -70.26% |
| 2011 Q1 | 9.7 Billion KRW | 0.0% |
| 2011 Q2 | 8.63 Billion KRW | -10.95% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 18.58 Billion KRW | -43.41% |
| 2010 Q3 | 6.52 Billion KRW | 73.5% |
| 2010 Q2 | 3.76 Billion KRW | 0.0% |
| 2009 FY | 32.84 Billion KRW | 81.09% |
| 2009 Q2 | 4.25 Billion KRW | 0.0% |
| 2009 Q3 | 7.33 Billion KRW | 72.38% |
| 2009 Q4 | 10.05 Billion KRW | 37.01% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 4.25 Billion KRW | -15.32% |
| 2008 Q2 | 2.98 Billion KRW | 0.0% |
| 2008 Q3 | 5.02 Billion KRW | 68.3% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | 18.13 Billion KRW | -19.83% |
| 2007 Q3 | 6.41 Billion KRW | 48.83% |
| 2007 FY | 22.62 Billion KRW | -2.13% |
| 2007 Q4 | 2.18 Billion KRW | -66.02% |
| 2007 Q2 | 4.31 Billion KRW | 0.0% |
| 2006 FY | 23.11 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -729.796% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 202.754% |
| HANDOK Inc. | -28.79 Billion KRW | -106.917% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -608.086% |
| Yuhan Corporation | 93.5 Billion KRW | 163.723% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 635.734% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -140.153% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 140.748% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 1798.303% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -2277.372% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -2773.163% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -1216.883% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 366.813% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -729.796% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -184.548% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 1762.869% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 49.618% |
| JW Holdings Corporation | 19.02 Billion KRW | 413.182% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 24.505% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 128.038% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 261.018% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -3.945% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 1073.361% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 3681.929% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 1290.606% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -729.796% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 261.195% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 153.44% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 261.018% |
| Yuhan Corporation | 93.5 Billion KRW | 163.723% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -266.694% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -1437.508% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 1073.764% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 261.018% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 415.178% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 223.466% |
| CKD Bio Corp. | -24.19 Billion KRW | -146.303% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 349.141% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 317.167% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 300.128% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -3.945% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 226.76% |
| Boryung Corporation | 40.2 Billion KRW | 248.216% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | -90.193% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -2277.372% |
| JW Lifescience Corporation | 28.14 Billion KRW | 311.721% |